Levosimendan was first approved for clinical use in 2000, when authorization was granted
by Swedish regulatory authorities for the hemodynamic stabilization of patients with acutely …

Left ventricular assist devices (LVADs) are increasingly common across the heart failure
population. Right ventricular failure (RVF) is a feared complication that can occur in the early …

Levosimendan is a distinctive inodilator combing calcium sensitization, phosphodiesterase
inhibition and vasodilating properties through the opening of adenosine triphosphate …

The inodilator levosimendan, in clinical use for over two decades, has been the subject of
extensive clinical and experimental evaluation in various clinical settings beyond its …

Left ventricular assist device (LVAD) therapy has been instrumental in saving lives of
patients with end-stage heart failure (HF). Recent generation devices have short-to-mid-term …

Levosimendan is an inodilator drug that, given its unique pharmacological actions and
safety profile, represents a viable therapeutic option in patients with heart failure with …

Right heart failure (RHF) following implantation of a left ventricular assist device (LVAD) is a
common and potentially serious condition with a wide spectrum of clinical presentations with …

OBJECTIVES Early right-sided heart failure (RHF) was seen in 22% of recipients of a left
ventricular assist device (LVAD) in the European Registry for Patients with Mechanical …

The use of left ventricular assist devices (LVAD) has significantly increased in the last years,
trying to offer a therapeutic alternative to heart transplantation, in light also to the significant …

OBJECTIVES Perioperative mortality and complications still remain high after left ventricular
assist device (LVAD) implantation, especially in highly compromised patient cohorts. Here …